BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260319T190000
DTEND;TZID=Africa/Nairobi:20260319T203000
DTSTAMP:20260527T063630
CREATED:20260318T112347Z
LAST-MODIFIED:20260319T174535Z
UID:41463-1773946800-1773952200@kesho-kenya.org
SUMMARY:Renal Cell Carcinoma: Evidence-Based Integration of Surgery and Systemic Therapy
DESCRIPTION:Evidence-Based Integration of Surgery and Systemic Therapy \nDate: 19th March 2026Time: 7 PM – 8:30 PM EAT \nMODERATORDr. Amina K. HabibMedical Oncologist\, Aga Khan University Hospital\, Nairobi \nDr. Carnjini YogeswaranConsultant Urological Surgeon | Kenyatta National HospitalTopic: Surgical Management of Locally Advanced and Oligometastatic Renal Cell Carcinoma \nDr. Douglas NyandikaPhysician and Medical Oncologist | The Nairobi HospitalTopic: Adjuvant and Metastatic Systemic Therapy in Renal Cell Carcinoma \nHighlights\nThis session examined the evolving management of renal cell carcinoma (RCC)\, focusing on how surgical and systemic approaches are increasingly integrated across the disease continuum. \nA central theme was the importance of risk-adapted\, multidisciplinary care\, particularly in settings where many patients are still present with advanced diseases. While improved imaging has increased incidental detection globally\, late-stage presentation remains common in Kenya\, shaping both prognosis and treatment strategy. \nFrom a surgical perspective\, nephron-sparing surgery remains standard for localized diseases\, while radical nephrectomy and complex resections play a critical role in locally advanced cases. In oligometastatic disease\, cytoreductive nephrectomy and metastasis-directed therapy may offer benefit in carefully selected patients\, particularly when integrated with systemic treatment strategies. \nSystemic therapy has expanded significantly\, with immune checkpoint inhibitors and targeted therapies now forming the backbone of treatment in advanced disease. Evidence from key trials demonstrates improved survival outcomes with combination regimens\, reinforcing a shift towards early and strategic use of systemic therapy\, particularly in metastatic and high-risk settings. \nIn the adjuvant setting\, therapies such as pembrolizumab have shown disease-free and overall survival benefit in selected high-risk patients\, highlighting the importance of post-surgical risk stratification and follow-up. \nHowever\, translating these advances into routine practice remains constrained by access\, cost and infrastructure. The discussion underscored the need for context-specific treatment pathways\, supported by multidisciplinary decision-making and strengthened health systems. \nAcross the session\, a consistent message emerged: optimal RCC outcomes depend on deliberate integration—of surgery\, systemic therapy and patient-centered decision-making. \nKey Takeaways \n\nRCC management requires integration of surgical and systemic therapies.\nLate-stage presentation remains a key challenge in many settings.\nNephron-sparing and radical surgery remain central to localized and advanced disease.\nImmunotherapy and targeted agents are transforming metastatic RCC outcomes.\nAdjuvant therapy is increasingly relevant in high-risk post-surgical patients.\nAccess\, cost and infrastructure continue to shape real-world implementation.\n\n 
URL:https://kesho-kenya.org/event/renal-cell-carcinoma-2/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-18-at-10.33.25-AM-e1773833004541.jpeg
END:VEVENT
END:VCALENDAR